Document Type

Journal Article

Publication Title

Australasian Journal on Ageing

Volume

42

Issue

1

First Page

251

Last Page

257

PubMed ID

36480154

Publisher

Wiley

School

School of Medical and Health Sciences / Nutrition and Health Innovation Research Institute

RAS ID

54125

Funders

National Health and Medical Research Council

Further funding information : https://doi.org/10.1111/ajag.13164

Grant Number

NHMRC Numbers : APP2005987, 1102208, 2003179

Comments

Zanker, J., Sim, M., Anderson, K., Balogun, S., Brennan‐Olsen, S. L., Dent, E., ... & Scott, D. (2023). The Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) sarcopenia diagnosis and management task force: Findings from the consumer expert Delphi process. Australasian Journal on Ageing, 42(1), 251-257. https://doi.org/10.1111/ajag.13164

Abstract

Objectives:

To develop guidelines, informed by health-care consumer values and preferences, for sarcopenia prevention, assessment and management for use by clinicians and researchers in Australia and New Zealand.

Methods:

A three-phase Consumer Expert Delphi process was undertaken between July 2020 and August 2021. Consumer experts included adults with lived experience of sarcopenia or health-care utilisation. Phase 1 involved a structured meeting of the Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) Sarcopenia Diagnosis and Management Task Force and consumer representatives from which the Phase 2 survey was developed. In Phase 2, consumers from Australia and New Zealand were surveyed online with opinions sought on sarcopenia outcome priorities, consultation preferences and interventions. Findings were confirmed and disseminated in Phase 3. Descriptive statistical analyses were performed.

Results:

Twenty-four consumers (mean ± standard deviation age 67.5 ± 12.8 years, 18 women) participated in Phase 2. Ten (42%) identified as being interested in sarcopenia, 7 (29%) were health-care consumers and 6 (25%) self-reported having/believing they have sarcopenia. Consumers identified physical performance, living circumstances, morale, quality of life and social connectedness as the most important outcomes related to sarcopenia. Consumers either had no preference (46%) or preferred their doctor (40%) to diagnose sarcopenia and preferred to undergo assessments at least yearly (54%). For prevention and treatment, 46% of consumers preferred resistance exercise, 2–3 times per week (54%).

Conclusions:

Consumer preferences reported in this study can inform the implementation of sarcopenia guidelines into clinical practice at local, state and national levels across Australia and New Zealand.

DOI

10.1111/ajag.13164

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Included in

Public Health Commons

Share

 
COinS